FOR MORE INFORMATION: Company Contact: Jill Blumhoff Chief Financial Officer & Vice President of Finance Phone: 765.497.8381 jblumhoff@BASinc.com BASi Reports Second Quarter Results

BASi Reports Second Quarter

WEST LAFAYETTE, IN, May

15, 2018 - Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi", the "Company", "We" or "Our")

today announced financial results for the second quarter and first six months of fiscal 2018.

Second Quarter Results

For the three months ended March

31, 2018, revenue amounted to $5,944,000 a 6% decrease from $6,359,000 in the second quarter of fiscal 2017.

Service revenue for the second

quarter of fiscal 2018 increased 1% to $5,030,000 compared to $4,962,000 for the same period in fiscal 2017. Preclinical services

revenue increased due to the mix and number of studies compared to the prior fiscal year period. Other laboratory services revenues

were negatively impacted by lower discovery services, which impact was partially offset by higher pharmaceutical analysis revenues

in the second quarter of fiscal 2018 versus the comparable period in fiscal 2017. In addition, archive revenue decreased in the

second quarter of fiscal 2018, as compared to the second quarter of fiscal 2017. Bioanalytical analysis revenues remained relatively

even when compared to the prior year period.

Sales in our Products segment

decreased 35% in the second quarter of fiscal 2018 from $1,397,000 to $914,000 when compared to the same period in the prior fiscal

year. The majority of the decrease stems from a decline in sales of our Culex automated in vivo sampling systems. This factor

was partially offset by an increase in our analytical instruments revenues.

Gross profit decreased to $1,740,000,

or 29% of revenue, in the second quarter of fiscal 2018, compared to $2,043,000, or 32% of revenue, during the comparable fiscal

2017 period. The principal causes for the decrease were a decline in product revenues and a less favorable revenue mix.

Operating expenses for the second

quarter of fiscal 2018 increased 10% to $1,630,000 compared to $1,488,000 during the second quarter of fiscal 2017. The principal

reasons for the increase were higher consulting costs related to new product development as well as employee search fees and increased

stock option expense attributable to the grants of options to our directors and certain employees in October 2017.

Operating income for the second

quarter of fiscal 2018 amounted to $110,000 compared to operating income of $555,000 for the second quarter of fiscal 2017. The

decrease was primarily due to lower revenue and higher operating expenses.

Net income for the second quarter

of fiscal 2018 amounted to $55,000, or $0.01 per diluted share, compared to a net income of $417,000, or $0.05 per diluted share

for the second quarter of fiscal 2017.

Adjusted EBITDA for the second

quarter of fiscal 2018, amounted to $524,000, compared to Adjusted EBITDA for the second quarter of fiscal 2017 of $937,000.

For the six months ended March

31, 2018, revenue amounted to $11,321,000 a 10% decrease from $12,533,000 for the six months ended March 31, 2017.

Service revenue decreased 7%

in the six months ended March 31, 2018 to $9,555,000 from $10,226,000 in the first six months of fiscal 2017. Preclinical services

revenues decreased due an unfavorable mix of studies performed year over year. Bioanalytical analysis revenues decreased due to

fewer samples received and analyzed in the first six months of fiscal 2018 in addition to an unfavorable mix favoring method development

and validation projects during this time period, which generate lower revenue but involve more dedicated resources. Other laboratory

services revenues were negatively impacted by lower discovery services and archive revenues, which were slightly offset by higher

pharmaceutical analysis revenues in the first six months of fiscal 2018 versus the comparable period in fiscal 2017.

Sales in our Products segment

decreased 23% in the six months ended March 31, 2018, from $2,307,000 to $1,766,000 when compared to the same period in the prior

fiscal year. The majority of the decrease stems from lower sales of our Culex automated in vivo sampling systems, offset

slightly by an increase in sales of our analytical instruments, over the same period in the prior fiscal year.

Gross profit in the six months

ended March 31, 2018 decreased to $3,321,000, or 29% of revenue, compared to $3,902,000, or 31% of revenue, for the same period

of the prior fiscal year. The decline was driven by a decrease in revenues which led to a lower absorption of fixed costs and an

unfavorable change in sales mix.

Operating expenses for the six

months ended March 31, 2018 decreased slightly to $3,200,000 from $3,253,000 for the comparable fiscal 2017 period. The principal

reason for the decrease was the accrual for the severance for our former Chief Executive Officer, amounting to approximately $200,000,

recorded in the first six months of fiscal 2017. This item was offset in part by increased consulting costs for new product development,

employee search fees and higher stock option expense attributable to the grants of options to our directors and certain employees

Operating income for the first

six months of fiscal 2018 amounted to $121,000 compared to an operating income of $649,000 for the first six months of fiscal 2017.

The decrease was primarily due to lower revenue partially offset by the decrease in operating expenses.

Net income amounted to $81,000,

or $0.01 per diluted share, for the first six months of fiscal 2018 compared to $434,000, or $0.05 per diluted share, for the first

six months of fiscal 2017.

Adjusted EBITDA was $969,000

for the first six months of fiscal 2018, compared to Adjusted EBITDA of $1,417,000 for the first six months of fiscal 2017.

Cash Provided by Operating

Cash provided by operating activities

was $842,000 for the first six months of fiscal 2018 compared to $561,000 for the first six months of fiscal 2017.

Accounts payable decreased by

$214,000 and inventory increased by $87,000, respectively. These items were offset in part by an increase in accrued expenses and

customer advances of $81,000 and $127,000, respectively, and a decrease in prepaid expenses and other assets of $72,000.

The Company had $672,000 in

cash and cash equivalents and $2,000,000 available on its line of credit as of March 31, 2018. During the first six

months of fiscal 2018, cash from operations funded capital expenditures for laboratory equipment and building improvements as well

as computer equipment and software of approximately $433,000.

Jill Blumhoff, BASi's

Vice President of Finance and Chief Financial Officer commented, "We are very pleased to report that the growth initiatives

underway for fiscal 2018 that we discussed at the end of fiscal 2017 and the first quarter of this year are beginning to demonstrate

results. The revenue reported for our second quarter was our highest quarterly achievement since the second quarter one year ago."

Ms. Blumhoff continued, "We

are beginning to deliver on our commitments. For example, the recently announced technology alliance with Phlebotics, Inc. is the

latest of BASi partnerships, including those with Joanneum Research and PalmSens, to expand our products and services offerings

that improve data and increase the speed of bringing new drugs to market. With the retirement of James Bourdage, Ph.D., Michael

Baim, Ph.D., has assumed the role of Vice President of Bioanalytical Operations. Dr. Michael Baim is an energetic and passionate

leader who brings to BASi over thirty years of experience in the pharmaceutical and lab management industries. He is well-versed

in analytical methodology and project design and has a proven track record of delivering significant and sustainable profitable

growth across many different business segments. We plan to continue making progress in enhancing the scientific expertise of our

staff. Lastly, we continue taking the necessary steps to make the expansion of our preclinical services facilities a reality.

We believe that cash on-hand

and, if needed, borrowings under our untapped revolving credit facility, should provide our team with the liquidity and flexibility

to fund our operating initiatives in order to deliver consistent profitable growth. We are encouraged once again by our results

thanks to the outstanding work from our dedicated employees. With the continued support from our board members and shareholders,

we will continue to execute on our initiatives," Ms. Blumhoff concluded.

Non-GAAP to GAAP Reconciliation

This press release contains

financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (GAAP).

The non-GAAP financial measures are Adjusted EBITDA for the first six months of fiscal 2018 and 2017. Adjusted EBITDA as reported

herein refers to a financial performance measure that excludes income statement line items interest expense and income taxes (benefit)

expense, as well as non-cash charges for depreciation and amortization and stock option (benefit) expense.

The non-GAAP financial information

should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance